Tags : Tango

PharmaShots Weekly Snapshot (Sept 07 -11, 2020)

1. Janssen’s Tremfya (guselkumab) Receives the US FDA’s Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis Published: Sept 10, 2020 | Tags:  Janssen, Tremfya, Guselkumab, Biologic, US FDA, Selective, IL-23 inhibitor, Active Psoriatic Arthritis, Severe Plaque Psoriasis, human mAb 2. Janssen Reports sBLA Submission to the US FDA for Darzalex Faspro (daratumumab […]Read More

PharmaShots Weekly Snapshot (Aug 17 -21 2020)

1. BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia Published: Aug 20, 2020 | Tags:  BioMarin, Reports, NDA, Submission, US, FDA, Vosoritide, Children, Achondroplasia 2. Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China Published: Aug 20, 2020 | Tags:  Junshi, Impact, Establish, Joint Venture, […]Read More

Gilead Expands its Oncology Collaboration with Tango for ~$6.3B

Shots: Tango to receive $125M up front, $20M as equity investment, up to $410M/ program as an opt-in, extension, and milestones along with royalties on sales of the products. If Tango opts to co-develop and co-promote the product, the parties will equally split profits/losses and development costs in the US and will receive milestones and […]Read More

ViiV Healthcare Reports Results of Dual-Drug Regimen in P-III TANGO

Shots: The P-III TANGO study involves assessing of Tivicay (dolutegravir) + Epivir (lamivudine) vs tenofovir alafenamide fumarate (TAF) -containing regimen in patients with HIV-1 with maintained viral suppression for at least 6mos. on TAF containing regimen The P-III TANGO study resulted in meeting its 1 EPs i.e, patients with plasma HIV-1 RNA ≥50 c/mL using […]Read More

Gilead Signs Global Research Collaboration with Tango to Develop &

Shots: Tango to get $50M upfront plus $1.7B as preclinical fees and milestone payments in addition to royalties in response Gilead has option to license WW rights to five targets developed from Tango’s genomics-based discovery platform Additionally, Tango has option to co-develop and co-retain two program from the above five targets in the US & […]Read More